title: Calcium antagonists in the prevention of motion sickness.
abstract: Flunarizine is a calcium antagonist which has proved clinically useful in controlling chronic vertigo. In a double blind crossover trial 10 subjects were used to compare the electronystagmic responses to motion in patients taking flunarizine, prochlorperazine maleate, or placebo. Flunarizine is shown to be a powerful peripherally acting labyrinthine suppressant, with application in the prevention of motion sickness. Flunarizine produces none of the central depressive side effects characteristic of antihistamines and anticholinergics, which are the conventional anti-motion sickness drugs.
mesh_terms: D000328:Adult; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002936:Cinnarizine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004584:Electronystagmography; D005444:Flunarizine; D006801:Humans; D008297:Male; D009041:Motion Sickness / Q000517:prevention & control*; D011346:Prochlorperazine / Q000627:therapeutic use; D014717:Vertigo / Q000188:drug therapy
chemical_list: D002121:Calcium Channel Blockers; D002936:Cinnarizine; D005444:Flunarizine; D011346:Prochlorperazine